GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (NAS:CDXS) » Definitions » Cyclically Adjusted PS Ratio

Codexis (Codexis) Cyclically Adjusted PS Ratio : 1.82 (As of Apr. 27, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Codexis Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Codexis's current share price is $2.66. Codexis's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.46. Codexis's Cyclically Adjusted PS Ratio for today is 1.82.

The historical rank and industry rank for Codexis's Cyclically Adjusted PS Ratio or its related term are showing as below:

CDXS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.64   Med: 3.53   Max: 27.14
Current: 1.81

During the past years, Codexis's highest Cyclically Adjusted PS Ratio was 27.14. The lowest was 0.64. And the median was 3.53.

CDXS's Cyclically Adjusted PS Ratio is ranked better than
74.26% of 505 companies
in the Biotechnology industry
Industry Median: 5.24 vs CDXS: 1.81

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Codexis's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.382. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.46 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Codexis Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Codexis's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codexis Cyclically Adjusted PS Ratio Chart

Codexis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.58 13.79 21.91 3.28 2.08

Codexis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.28 2.90 1.93 1.29 2.08

Competitive Comparison of Codexis's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Codexis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Codexis's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codexis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Codexis's Cyclically Adjusted PS Ratio falls into.



Codexis Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Codexis's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.66/1.46
=1.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Codexis's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Codexis's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.382/129.4194*129.4194
=0.382

Current CPI (Dec. 2023) = 129.4194.

Codexis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.184 99.695 0.239
201406 0.173 100.560 0.223
201409 0.194 100.428 0.250
201412 0.367 99.070 0.479
201503 0.175 99.621 0.227
201506 0.153 100.684 0.197
201509 0.425 100.392 0.548
201512 0.292 99.792 0.379
201603 0.200 100.470 0.258
201606 0.385 101.688 0.490
201609 0.353 101.861 0.449
201612 0.243 101.863 0.309
201703 0.193 102.862 0.243
201706 0.219 103.349 0.274
201709 0.207 104.136 0.257
201712 0.451 104.011 0.561
201803 0.290 105.290 0.356
201806 0.256 106.317 0.312
201809 0.316 106.507 0.384
201812 0.298 105.998 0.364
201903 0.288 107.251 0.348
201906 0.224 108.070 0.268
201909 0.357 108.329 0.427
201912 0.318 108.420 0.380
202003 0.249 108.902 0.296
202006 0.254 108.767 0.302
202009 0.311 109.815 0.367
202012 0.348 109.897 0.410
202103 0.280 111.754 0.324
202106 0.395 114.631 0.446
202109 0.543 115.734 0.607
202112 0.377 117.630 0.415
202203 0.543 121.301 0.579
202206 0.588 125.017 0.609
202209 0.527 125.227 0.545
202212 0.463 125.222 0.479
202303 0.197 127.348 0.200
202306 0.316 128.729 0.318
202309 0.134 129.860 0.134
202312 0.382 129.419 0.382

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Codexis  (NAS:CDXS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Codexis Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Codexis's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Codexis (Codexis) Business Description

Industry
Traded in Other Exchanges
Address
200 Penobscot Drive, Redwood, CA, USA, 94063
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases, etc. The company operates in two business segments namely Performance Enzymes and Novel Biotherapeutics. It generates maximum revenue from the Performance Enzymes segment. Geographically, it derives a majority of revenue from the APAC.
Executives
Byron L Dorgan director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Norrett officer: Chief Operating Officer C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Margaret Nell Fitzgerald officer: See Remarks ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Sriram Ryali officer: Chief Financial Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Stephen George Dilly director, officer: See Remarks C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
John J Nicols director, officer: President and CEO ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
H Stewart Parker director
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Dennis P Wolf director 1101 EAST MEADOW DR, PALO ALTO CA 94303
Patrick Y Yang director C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
Bernard J Kelley director
Esther Martinborough director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Jennifer Aaker director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Alison Moore director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Thomas R Baruch director 1 LETTERMAN DRIVE, BUILDING C, SUITE CM500, SAN FRANCISCO CA 94129